2024-09-01 2025-08-31 false No description of principal activity Acting Office - Tax and Accounts 1.0 13581609 bus:FullAccounts 2024-09-01 2025-08-31 13581609 bus:FRS102 2024-09-01 2025-08-31 13581609 bus:AuditExempt-NoAccountantsReport 2024-09-01 2025-08-31 13581609 bus:SmallCompaniesRegimeForAccounts 2024-09-01 2025-08-31 13581609 bus:PrivateLimitedCompanyLtd 2024-09-01 2025-08-31 13581609 2024-09-01 2025-08-31 13581609 2025-08-31 13581609 bus:RegisteredOffice 2024-09-01 2025-08-31 13581609 core:WithinOneYear 2025-08-31 13581609 core:AfterOneYear 2025-08-31 13581609 2023-09-01 13581609 bus:Director1 2024-09-01 2025-08-31 13581609 bus:Director1 2025-08-31 13581609 bus:Director1 2023-09-01 2024-08-31 13581609 bus:Director2 2024-09-01 2025-08-31 13581609 bus:Director2 2025-08-31 13581609 bus:Director2 2023-09-01 2024-08-31 13581609 bus:CompanySecretary1 2024-09-01 2025-08-31 13581609 bus:LeadAgentIfApplicable 2024-09-01 2025-08-31 13581609 2023-09-01 2024-08-31 13581609 2024-08-31 13581609 core:WithinOneYear 2024-08-31 13581609 core:AfterOneYear 2024-08-31 13581609 bus:EntityAccountantsOrAuditors 2023-09-01 2024-08-31 13581609 core:OfficeEquipment 2024-09-01 2025-08-31 13581609 core:OfficeEquipment 2025-08-31 13581609 core:OfficeEquipment 2024-08-31 13581609 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2025-08-31 13581609 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2024-08-31 13581609 core:CostValuation core:Non-currentFinancialInstruments 2025-08-31 13581609 core:CostValuation core:Non-currentFinancialInstruments 2024-08-31 13581609 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-08-31 13581609 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2025-08-31 13581609 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-08-31 13581609 core:ShareProfitOrLossIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-08-31 13581609 core:ProvisionsForImpairmentInvestments core:Non-currentFinancialInstruments 2025-08-31 13581609 core:ImpairmentReversalProvisionsForImpairmentInvestments core:Non-currentFinancialInstruments 2025-08-31 13581609 core:ForeignExchangeDifferencesIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-08-31 13581609 core:TransfersIntoOrOutInvestmentsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-08-31 13581609 core:TransfersBetweenInvestmentClassesIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-08-31 13581609 core:Non-currentFinancialInstruments 2025-08-31 13581609 core:Non-currentFinancialInstruments 2024-08-31 13581609 core:ShareCapital 2025-08-31 13581609 core:ShareCapital 2024-08-31 13581609 core:RetainedEarningsAccumulatedLosses 2025-08-31 13581609 core:RetainedEarningsAccumulatedLosses 2024-08-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 13581609
England and Wales

 

 

 


Unaudited Financial Statements

for the year ended 31 August 2025

for

BURLINGTON PHARMA LTD

 
 
Notes
 
2025
£
  2024
£
Fixed assets
Tangible fixed assets 2 3,275    4,093 
3,275    4,093 
Current assets
Debtors 3 41,376    20,841 
Cash at bank and in hand 121,146    87,997 
162,522    108,838 
Creditors: amount falling due within one year 4 (49,442)   (55,342)
Net current assets/(liabilities) 113,080    53,496 
 
Total assets less current liabilities 116,355    57,589 
Net assets/(liabilities) 116,355    57,589 
 

Capital and reserves
Called up share capital 100    100 
Profit and loss account 5 116,255    57,489 
Shareholders fund 116,355    57,589 
 
For the year ended 31 August 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' Responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006.
  2. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime of Part 15 of the Companies Act 2006.
Signed on behalf of the board of directors:


---------------------------------------------
Cheung Hoe Leong
Director

Date approved: 18 May 2026
1
Statutory Information
Burlington Pharma Ltd is a private limited company, limited by shares, domiciled in England and Wales, registration number 13581609, registration address Unit 217b Mirror Works 12 Marshgate Lane, London, E15 2NH, England.

The presentation currency is £ sterling.
1.

Accounting Policies

Basis of accounting
The financial statements are prepared under the historical cost convention and in accordance with the FRS 102 Financial Reporting Standard for Smaller Entities (effective January 2016).
Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates and sales taxes.

Turnover from the sale of goods is recognised when all of the following conditions are satisfied:

• the company has transferred the significant risks and rewards of ownership to the buyer;
• the company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
• the amount of revenue can be measured reliably;
• it is probable that the company will receive the consideration due under the transaction; and
• the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services
Turnover from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
• the amount of revenue can be measured reliably;
• it is probable that the Company will receive the consideration due under the contract;
• the stage of completion of the contract at the end of the reporting period can be measured reliably; and
• the costs incurred and the costs to complete the contract can be measured reliably.

Where a contract has only been partially completed at the Balance Sheet date turnover represents the fair value of the service provided to date based on the stage of completion of the contract activity at the Balance Sheet date.

Where payments are received from customers in advance of services provided, the amounts are recorded as deferred income and included as part of creditors due within one year.
Website cost
Planning and operating costs for the company's website are charged to the profit and loss account as incurred.
Taxation
Current tax, including UK corporation tax and foreign tax, is provided at amounts expected to be paid (or recovered) using the tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.
Dividends
Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

Proposed dividends are only included as liabilities in the financial statements when their payment has been approved by the shareholders prior to the balance sheet date.
Tangible fixed assets
Tangible fixed assets, other than freehold land, are stated at historical cost or valuation less depreciation and any provision for impairment. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:

Employee benefits
Short-term employee benefits are recognised as an expense in the period in which they are incurred.

Long-term employee benefits are measured at the present value of the benefit obligation at the reporting date.

Termination benefits are recognised as an expense when the Company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
Finance costs
Finance costs are charged to the Profit and Loss Account over the term of the debt using the effective interest method so the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.
Cash and cash equivalents
Cash and cash equivalents are highly liquid investments and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.
Trade and other creditors
Short-term creditors are measured at the transaction price. The other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, unless the effect of discounting would be immaterial, in which case they are stated at cost.
Equity instruments
Equity instruments issued by the Company are recorded at the fair value of cash or other resources received or receivable, net of direct issue costs. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the Company.
Defined contribution schemes
The obligations for contributions to defined contribution scheme are recognised as an expense to the Profit and Loss Account in respect of pension costs and other post-retirement benefits, in the period they are incurred. The assets of the scheme are held separately from those of the company in an independently administered fund.

Differences between contributions payable in the financial year and contributions actually paid are shown as either accruals or prepayments in the Balance Sheet.
2.

Tangible fixed assets

Cost or Valuation   Office Equipment   Total
    £   £
At 01 September 2024   5,941    5,941 
Additions    
At 31 August 2025   5,941    5,941 
Depreciation
At 01 September 2024   1,848    1,848 
Charge for year   818    818 
At 31 August 2025   2,666    2,666 
Net book values
Closing balance as at 31 August 2025   3,275    3,275 
Opening balance as at 01 September 2024   4,093    4,093 
3.

Debtors: amounts falling due within one year

2025
£
  2024
£
VAT 41,376    20,841 
41,376    20,841 
4.

Creditors: amount falling due within one year

2025
£
  2024
£
Accrued expenses 399    1,000 
Other creditors 9,148    9,147 
Pension Payable 122    122 
Directors' current accounts 22,820    31,781 
Corporation tax 16,622    12,520 
Social security & other tax 331    772 
49,442    55,342 
5.

Profit and loss account

  2025
£
Balance at 01 September 2024 57,489 
Profit for the year 58,766 
Balance at 31 August 2025 116,255 

6.

Average number of employees

Average number of employees during the year were 2 (2024: 2).
2